Free Trial
→ SpaceX eyes a 1.75 trillion valuation - here's what to know (From Brownstone Research) (Ad)tc pixel Free RLAY Stock Alerts

Relay Therapeutics (RLAY) Competitors

Relay Therapeutics logo
$12.51 -0.41 (-3.17%)
Closing price 05/7/2026 04:00 PM Eastern
Extended Trading
$12.67 +0.16 (+1.30%)
As of 09:02 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

RLAY vs. ABVX, PRAX, PCVX, CYTK, and KRYS

Should you be buying Relay Therapeutics stock or one of its competitors? The main competitors of Relay Therapeutics include Abivax (ABVX), Praxis Precision Medicines (PRAX), Vaxcyte (PCVX), Cytokinetics (CYTK), and Krystal Biotech (KRYS). These companies are all part of the "pharmaceutical products" industry.

How does Relay Therapeutics compare to Abivax?

Relay Therapeutics (NASDAQ:RLAY) and Abivax (NASDAQ:ABVX) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation, risk and media sentiment.

Relay Therapeutics' return on equity of -44.45% beat Abivax's return on equity.

Company Net Margins Return on Equity Return on Assets
Relay TherapeuticsN/A -44.45% -40.50%
Abivax N/A -146.43%-88.69%

Relay Therapeutics presently has a consensus target price of $20.56, suggesting a potential upside of 64.31%. Abivax has a consensus target price of $137.15, suggesting a potential upside of 10.03%. Given Relay Therapeutics' higher possible upside, equities research analysts plainly believe Relay Therapeutics is more favorable than Abivax.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Relay Therapeutics
1 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.82
Abivax
1 Sell rating(s)
0 Hold rating(s)
13 Buy rating(s)
1 Strong Buy rating(s)
2.93

97.0% of Relay Therapeutics shares are held by institutional investors. Comparatively, 47.9% of Abivax shares are held by institutional investors. 4.9% of Relay Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Relay Therapeutics has a beta of 1.74, meaning that its stock price is 74% more volatile than the S&P 500. Comparatively, Abivax has a beta of 0.84, meaning that its stock price is 16% less volatile than the S&P 500.

Relay Therapeutics has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than Relay Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Relay Therapeutics$15.35M156.14-$276.48M-$1.62N/A
AbivaxN/AN/A-$380.27M-$5.37N/A

In the previous week, Relay Therapeutics and Relay Therapeutics both had 7 articles in the media. Abivax's average media sentiment score of 1.14 beat Relay Therapeutics' score of 0.20 indicating that Abivax is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Relay Therapeutics
2 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Abivax
4 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Relay Therapeutics beats Abivax on 10 of the 13 factors compared between the two stocks.

How does Relay Therapeutics compare to Praxis Precision Medicines?

Praxis Precision Medicines (NASDAQ:PRAX) and Relay Therapeutics (NASDAQ:RLAY) are both mid-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk, dividends and media sentiment.

Relay Therapeutics has higher revenue and earnings than Praxis Precision Medicines. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Relay Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Praxis Precision Medicines$8.55M1,086.38-$303.27M-$13.46N/A
Relay Therapeutics$15.35M156.14-$276.48M-$1.62N/A

In the previous week, Praxis Precision Medicines had 6 more articles in the media than Relay Therapeutics. MarketBeat recorded 13 mentions for Praxis Precision Medicines and 7 mentions for Relay Therapeutics. Praxis Precision Medicines' average media sentiment score of 0.88 beat Relay Therapeutics' score of 0.20 indicating that Praxis Precision Medicines is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Praxis Precision Medicines
5 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Relay Therapeutics
2 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

67.8% of Praxis Precision Medicines shares are held by institutional investors. Comparatively, 97.0% of Relay Therapeutics shares are held by institutional investors. 2.7% of Praxis Precision Medicines shares are held by company insiders. Comparatively, 4.9% of Relay Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Praxis Precision Medicines has a beta of 2.76, indicating that its stock price is 176% more volatile than the S&P 500. Comparatively, Relay Therapeutics has a beta of 1.74, indicating that its stock price is 74% more volatile than the S&P 500.

Relay Therapeutics' return on equity of -44.45% beat Praxis Precision Medicines' return on equity.

Company Net Margins Return on Equity Return on Assets
Praxis Precision MedicinesN/A -58.74% -53.54%
Relay Therapeutics N/A -44.45%-40.50%

Praxis Precision Medicines presently has a consensus price target of $590.78, suggesting a potential upside of 77.26%. Relay Therapeutics has a consensus price target of $20.56, suggesting a potential upside of 64.31%. Given Praxis Precision Medicines' stronger consensus rating and higher probable upside, analysts clearly believe Praxis Precision Medicines is more favorable than Relay Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Praxis Precision Medicines
2 Sell rating(s)
1 Hold rating(s)
12 Buy rating(s)
5 Strong Buy rating(s)
3.00
Relay Therapeutics
1 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.82

Summary

Praxis Precision Medicines and Relay Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Relay Therapeutics compare to Vaxcyte?

Vaxcyte (NASDAQ:PCVX) and Relay Therapeutics (NASDAQ:RLAY) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, risk, valuation and earnings.

Vaxcyte's return on equity of -32.83% beat Relay Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
VaxcyteN/A -32.83% -29.95%
Relay Therapeutics N/A -44.45%-40.50%

Vaxcyte currently has a consensus price target of $86.00, indicating a potential upside of 67.06%. Relay Therapeutics has a consensus price target of $20.56, indicating a potential upside of 64.31%. Given Vaxcyte's higher probable upside, equities research analysts plainly believe Vaxcyte is more favorable than Relay Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vaxcyte
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.63
Relay Therapeutics
1 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.82

96.8% of Vaxcyte shares are owned by institutional investors. Comparatively, 97.0% of Relay Therapeutics shares are owned by institutional investors. 3.1% of Vaxcyte shares are owned by insiders. Comparatively, 4.9% of Relay Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Vaxcyte had 3 more articles in the media than Relay Therapeutics. MarketBeat recorded 10 mentions for Vaxcyte and 7 mentions for Relay Therapeutics. Vaxcyte's average media sentiment score of 0.46 beat Relay Therapeutics' score of 0.20 indicating that Vaxcyte is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Vaxcyte
5 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Relay Therapeutics
2 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Vaxcyte has a beta of 1.3, meaning that its stock price is 30% more volatile than the S&P 500. Comparatively, Relay Therapeutics has a beta of 1.74, meaning that its stock price is 74% more volatile than the S&P 500.

Relay Therapeutics has higher revenue and earnings than Vaxcyte. Vaxcyte is trading at a lower price-to-earnings ratio than Relay Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
VaxcyteN/AN/A-$766.63M-$5.62N/A
Relay Therapeutics$15.35M156.14-$276.48M-$1.62N/A

Summary

Relay Therapeutics beats Vaxcyte on 9 of the 15 factors compared between the two stocks.

How does Relay Therapeutics compare to Cytokinetics?

Cytokinetics (NASDAQ:CYTK) and Relay Therapeutics (NASDAQ:RLAY) are both mid-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, valuation, analyst recommendations, profitability, media sentiment and risk.

Relay Therapeutics has a net margin of 0.00% compared to Cytokinetics' net margin of -784.02%. Cytokinetics' return on equity of 0.00% beat Relay Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Cytokinetics-784.02% N/A -52.86%
Relay Therapeutics N/A -44.45%-40.50%

Cytokinetics presently has a consensus target price of $97.25, indicating a potential upside of 30.91%. Relay Therapeutics has a consensus target price of $20.56, indicating a potential upside of 64.31%. Given Relay Therapeutics' higher possible upside, analysts clearly believe Relay Therapeutics is more favorable than Cytokinetics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cytokinetics
1 Sell rating(s)
3 Hold rating(s)
17 Buy rating(s)
1 Strong Buy rating(s)
2.82
Relay Therapeutics
1 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.82

97.0% of Relay Therapeutics shares are held by institutional investors. 2.6% of Cytokinetics shares are held by company insiders. Comparatively, 4.9% of Relay Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Cytokinetics had 37 more articles in the media than Relay Therapeutics. MarketBeat recorded 44 mentions for Cytokinetics and 7 mentions for Relay Therapeutics. Cytokinetics' average media sentiment score of 0.68 beat Relay Therapeutics' score of 0.20 indicating that Cytokinetics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cytokinetics
20 Very Positive mention(s)
4 Positive mention(s)
15 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Relay Therapeutics
2 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Cytokinetics has a beta of 0.38, suggesting that its stock price is 62% less volatile than the S&P 500. Comparatively, Relay Therapeutics has a beta of 1.74, suggesting that its stock price is 74% more volatile than the S&P 500.

Relay Therapeutics has lower revenue, but higher earnings than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than Relay Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cytokinetics$88.04M105.00-$784.96M-$6.53N/A
Relay Therapeutics$15.35M156.14-$276.48M-$1.62N/A

Summary

Relay Therapeutics beats Cytokinetics on 10 of the 15 factors compared between the two stocks.

How does Relay Therapeutics compare to Krystal Biotech?

Relay Therapeutics (NASDAQ:RLAY) and Krystal Biotech (NASDAQ:KRYS) are both mid-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership and risk.

Relay Therapeutics currently has a consensus target price of $20.56, suggesting a potential upside of 64.31%. Krystal Biotech has a consensus target price of $324.11, suggesting a potential upside of 9.24%. Given Relay Therapeutics' higher possible upside, analysts clearly believe Relay Therapeutics is more favorable than Krystal Biotech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Relay Therapeutics
1 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.82
Krystal Biotech
0 Sell rating(s)
2 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.83

Krystal Biotech has higher revenue and earnings than Relay Therapeutics. Relay Therapeutics is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Relay Therapeutics$15.35M156.14-$276.48M-$1.62N/A
Krystal Biotech$417.30M20.96$204.83M$7.4839.67

In the previous week, Krystal Biotech had 25 more articles in the media than Relay Therapeutics. MarketBeat recorded 32 mentions for Krystal Biotech and 7 mentions for Relay Therapeutics. Krystal Biotech's average media sentiment score of 0.74 beat Relay Therapeutics' score of 0.20 indicating that Krystal Biotech is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Relay Therapeutics
2 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Krystal Biotech
8 Very Positive mention(s)
5 Positive mention(s)
11 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

97.0% of Relay Therapeutics shares are owned by institutional investors. Comparatively, 86.3% of Krystal Biotech shares are owned by institutional investors. 4.9% of Relay Therapeutics shares are owned by insiders. Comparatively, 13.1% of Krystal Biotech shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Relay Therapeutics has a beta of 1.74, indicating that its stock price is 74% more volatile than the S&P 500. Comparatively, Krystal Biotech has a beta of 0.5, indicating that its stock price is 50% less volatile than the S&P 500.

Krystal Biotech has a net margin of 53.92% compared to Relay Therapeutics' net margin of 0.00%. Krystal Biotech's return on equity of 19.25% beat Relay Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Relay TherapeuticsN/A -44.45% -40.50%
Krystal Biotech 53.92%19.25%17.62%

Summary

Krystal Biotech beats Relay Therapeutics on 12 of the 17 factors compared between the two stocks.

Get Relay Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for RLAY and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RLAY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RLAY vs. The Competition

Export
MetricRelay TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$2.48B$3.17B$6.30B$12.14B
Dividend YieldN/A1.87%2.78%5.25%
P/E Ratio-7.9717.5228.4527.00
Price / Sales156.14295.36527.5575.93
Price / CashN/A56.3043.3053.97
Price / Book3.834.319.806.89
Net Income-$276.48M$72.19M$3.55B$333.11M
7 Day PerformanceN/AN/AN/A0.14%
1 Month Performance-13.78%4.32%5.19%6.78%
1 Year Performance313.55%46.57%40.37%38.93%

Relay Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RLAY
Relay Therapeutics
2.9954 of 5 stars		$12.51
-3.2%		$20.56
+64.3%		+332.3%$2.48B$15.35MN/A330
ABVX
Abivax
3.0331 of 5 stars		$117.13
-0.4%		$137.15
+17.1%		+1,766.0%$9.33BN/AN/A61
PRAX
Praxis Precision Medicines
3.3568 of 5 stars		$337.61
+4.1%		$590.78
+75.0%		+775.0%$9.03B$8.55MN/A110
PCVX
Vaxcyte
1.9367 of 5 stars		$58.49
+2.7%		$86.00
+47.0%		+77.5%$8.22BN/AN/A160
CYTK
Cytokinetics
3.37 of 5 stars		$66.05
+4.3%		$90.55
+37.1%		+124.8%$7.87B$88.04MN/A250

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:RLAY) was last updated on 5/8/2026 by MarketBeat.com Staff.
From Our Partners
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
The Death of the Nasdaq?
The Death of the Nasdaq? Wall Street legend Marc Chaikin's award-winning system turned bearish on software ...
Chaikin Analytics | Sponsoredtc pixel
‘Please’: OpenAI CEO Sam Altman Begs Small Company for Help
SpaceX 'Dark Energy' Replaces Foreign Oil For years, we've been told SpaceX is a rocket company. But accord...
Altimetry | Sponsoredtc pixel
One executive order. The biggest wealth transfer of your lifetime.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
I’m sounding the alarm
Meta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, ...
Porter & Company | Sponsoredtc pixel
Is the SpaceX IPO “Rigged?”
The SpaceX IPO filing is official, with 21 banks - including JPMorgan, Goldman Sachs, and Morgan Stanley - pre...
The Oxford Club | Sponsoredtc pixel